All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Visual abstract | A phase II trial of CD24Fc for GvHD prophylaxis

Oct 20, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in GvHD.

Bookmark this article

The GvHD Hub is pleased to present a visual abstract representing data from a phase II trial (NCT02663622) evaluating CD24Fc, a novel CD24 fusion protein, for graft-versus-host disease prophylaxis.1

This study, which was conducted in two parts (a double-blind dose-escalation phase and an open-label extension phase), evaluated the safety, recommended dose, and efficacy of CD24Fc in patients undergoing allogeneic hematopoietic stem cell transplantation.1 Overall, CD24Fc demonstrated improved graft-versus-host disease-free survival compared with matched controls, and no patients experienced dose-limiting toxicities.1


Visual abstract

To download this visual abstract, click below.

Download here

  1. Magenau J, Jaglowski S, Uberti J, et al. A phase 2 trial of CD24Fc for prevention of graft-vs-host disease. Blood. 2023. Online ahead of print. DOI: 1182/blood.2023020250


Subscribe to get the best content related to GvHD delivered to your inbox